Literature DB >> 12697994

Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction.

M Gross1, H Hanenberg, S Lobitz, R Friedl, S Herterich, R Dietrich, B Gruhn, D Schindler, H Hoehn.   

Abstract

Fanconi anemia (FA) is a genetically and phenotypically heterogenous autosomal recessive disease associated with chromosomal instability and hypersensitivity to DNA crosslinkers. Prognosis is poor due to progressive bone marrow failure and increased risk of neoplasia, but revertant mosaicism may improve survival. Mechanisms of reversion include back mutation, intragenic crossover, gene conversion and compensating deletions/insertions. We describe the types of reversions found in five mosaic FA patients who are compound heterozygotes for single base mutations in FANCA or FANCC. Intragenic crossover could be shown as the mechanism of self-correction in the FANCC patient. Restoration to wildtype via back mutation or gene conversion of either the paternal or maternal allele was observed in the FANCA patients. The sequence environments of these mutations/reversions were indicative of high mutability, and selective advantage of bone marrow precursor cells carrying a completely restored FANCA allele might explain the surprisingly uniform pattern of these reversions. We also describe a first example of in vitro phenotypic reversion via the emergence of a compensating missense mutation 15 amino acids downstream of the constitutional mutation, which explains the reversion to MMC resistance of the respective lymphoblastoid cell line. With one exception, our mosaic patients showed improvement of their hematological status during a three- to six-year observation period, indicating a proliferative advantage of the reverted cell lineages. In patients with Fanconi anemia, genetic instability due to defective caretaker genes sharply increases the risk of neoplasia, but at the same time increases the chance for revertant mosaicism leading to improved bone marrow function. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 12697994     DOI: 10.1159/000069805

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  54 in total

1.  Gene therapy for Fanconi anemia: one step closer to the clinic.

Authors:  Jakub Tolar; Pamela S Becker; D Wade Clapp; Helmut Hanenberg; Cristina Díaz de Heredia; Hans-Peter Kiem; Susana Navarro; Pankaj Qasba; Paula Rio; Manfred Schmidt; Julián Sevilla; Els Verhoeyen; Adrian J Thrasher; Juan Bueren
Journal:  Hum Gene Ther       Date:  2012-02       Impact factor: 5.695

Review 2.  Neonatal manifestations of inherited bone marrow failure syndromes.

Authors:  Payal P Khincha; Sharon A Savage
Journal:  Semin Fetal Neonatal Med       Date:  2015-12-24       Impact factor: 3.926

3.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

4.  Natural gene therapy in monozygotic twins with Fanconi anemia.

Authors:  Anuj Mankad; Toshiyasu Taniguchi; Barbara Cox; Yassmine Akkari; R Keaney Rathbun; Lora Lucas; Grover Bagby; Susan Olson; Alan D'Andrea; Markus Grompe
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

5.  HSP90 Shapes the Consequences of Human Genetic Variation.

Authors:  Georgios I Karras; Song Yi; Nidhi Sahni; Máté Fischer; Jenny Xie; Marc Vidal; Alan D D'Andrea; Luke Whitesell; Susan Lindquist
Journal:  Cell       Date:  2017-02-16       Impact factor: 41.582

6.  Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: Series of 9 cases and review of the literature.

Authors:  Thomas H Beckham; Jonathan Leeman; Chiaojung Jillian Tsai; Nadeem Riaz; Eric Sherman; Bhuvanesh Singh; Nancy Lee; Sean McBride; Daniel S Higginson
Journal:  Head Neck       Date:  2019-01-11       Impact factor: 3.147

Review 7.  Molecular pathogenesis and clinical management of Fanconi anemia.

Authors:  Younghoon Kee; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

8.  Clonal hematopoiesis in patients with dyskeratosis congenita.

Authors:  Nieves Perdigones; Juan C Perin; Irene Schiano; Peter Nicholas; Jaclyn A Biegel; Philip J Mason; Daria V Babushok; Monica Bessler
Journal:  Am J Hematol       Date:  2016-10-21       Impact factor: 10.047

9.  Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.

Authors:  P S Becker; J A Taylor; G D Trobridge; X Zhao; B C Beard; S Chien; J Adair; D B Kohn; J E Wagner; A Shimamura; H-P Kiem
Journal:  Gene Ther       Date:  2010-05-20       Impact factor: 5.250

10.  Diagnosis of Fanconi anemia in patients with bone marrow failure.

Authors:  Fernando O Pinto; Thierry Leblanc; Delphine Chamousset; Gwenaelle Le Roux; Benoit Brethon; Bruno Cassinat; Jérôme Larghero; Jean-Pierre de Villartay; Dominique Stoppa-Lyonnet; André Baruchel; Gérard Socié; Eliane Gluckman; Jean Soulier
Journal:  Haematologica       Date:  2009-03-10       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.